Skip to main content

Table 3 Monitoring of NPTX2 methylation frequencies

From: Circulating NPTX2 methylation as a non-invasive biomarker for prognosis and monitoring of metastatic pancreatic cancer

Methylation monitoring

n

BMP3m

NPTX2m

SPARCm

SFRP1m

TFPI2m

To diagnosis

8

5 (62.5%)

7 (87.5%)

1 (12.5%)

1 (12.5%)

1 (12.5%)

After treatment

24

4 (16.67%)

16 (66.67%)

1 (4.17%)

3 (12.5%)

1 (4.17%)